/Investor DB

Access Industries — 2024 Investments

4 investments dated 2024 · listed companies and verified rows first · show all

All Things Butterallthingsbutter.comMay 2024

British dairy company producing butter and other products from grass-fed cows, co-founded by a chef

Co-investorsActive Partners

Grobiogrobio.comin𝕏Series B · Jul 2024 · $60M

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Chief Executive Officer)Tracey Lodie(Executive Officer)inChristopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Co-investorsLeaps by BayerREDMILEAlumni VenturesDigitalis VenturesDreamers VCRising Tide+3 more

Numericnumeric.ioinOct 2024

Numeric builds a software platform for corporate finance and accounting teams that combines real-time accounting, data transformation, and AI-powered analytics to replace manual spreadsheet-based processes.

AI & Machine LearningEnterprise SoftwareFintechSan Francisco, US

Parker Gilbert(Founder)inAndrew Bihl(Founder)inAnthony Alvernaz(Founder)in

Co-investorsAlkeon InnovationArtisanal VenturesFifth Down CapitalHawk Hill VenturesIVP (Institutional Venture Partners)Long Journey Ventures+8 more

Santa Ana Biosantaana.bioinSeries B · Jun 2024 · $130M

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.

AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US

Peter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)Graham Lord(Scientific Founder)inAnsuman Satpathy(Scientific Founder)inNewman Yeilding(Chief Medical Officer)in

Co-investorsAccess BiotechnologyAndreessen HorowitzGV (Google Ventures)Versant VenturesRTW Investments L.P.TPG+1 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.